Clinical utility of applying a simple, low-cost methodic approach to evaluation of circulating tumor DNA ( ctDNA) in colorectal cancer patients undergoing surgical treatment

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F14%3A%230000226" target="_blank" >RIV/26475821:_____/14:#0000226 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Clinical utility of applying a simple, low-cost methodic approach to evaluation of circulating tumor DNA ( ctDNA) in colorectal cancer patients undergoing surgical treatment

Popis výsledku v původním jazyce

Poster at UEGWeek 2014 describing low-cost methodic approach to evaluation of circulating tumor DNA in colorectal cancer patients. Circulating tumor DNA (ctDNA) is currently a very promising marker for non-invasive management of patients with cancer. ctDNA consists of short DNA fragments originating from the tumor tissue, which occur freely in the peripheral blood of the patients, predominantly in advanced stages. The main clinical significance of ctDNA , according to recent studies, is in monitoring patients after tumor resection, detection of recurrence or progression of disease and predictingand monitoring the response to treatment. Most methods for ctDNA detection and monitoring are based on highly dedicated technologies (digital PCR with subsequent detection by flow cytometry or next-generation sequencing) and the high cost of equipment as well as sample processing prevents wide application of ctDNA testing in a clinical practice. We present here a routine procedure for the ctDNA

Název v anglickém jazyce

Clinical utility of applying a simple, low-cost methodic approach to evaluation of circulating tumor DNA ( ctDNA) in colorectal cancer patients undergoing surgical treatment

Popis výsledku anglicky

Poster at UEGWeek 2014 describing low-cost methodic approach to evaluation of circulating tumor DNA in colorectal cancer patients. Circulating tumor DNA (ctDNA) is currently a very promising marker for non-invasive management of patients with cancer. ctDNA consists of short DNA fragments originating from the tumor tissue, which occur freely in the peripheral blood of the patients, predominantly in advanced stages. The main clinical significance of ctDNA , according to recent studies, is in monitoring patients after tumor resection, detection of recurrence or progression of disease and predictingand monitoring the response to treatment. Most methods for ctDNA detection and monitoring are based on highly dedicated technologies (digital PCR with subsequent detection by flow cytometry or next-generation sequencing) and the high cost of equipment as well as sample processing prevents wide application of ctDNA testing in a clinical practice. We present here a routine procedure for the ctDNA

Druh

O - Ostatní výsledky

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13660" target="_blank" >NT13660: Hodnocení kvality multimodální péče u nemocných s jaterními metastázami kolorektálního karcinomu v rámci komplexních onkologických center ČR Multicentrická studie</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů